Cargando…

CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review

PURPOSE: The purpose is to characterize the CYP2D6 genotype and predict the phenotype of decedents of opioid overdose to determine if the ultrarapid (UM) phenotype is over-represented in opioid overdose deaths. CYP2D6 is the enzyme responsible for metabolism of various opioids implicated in overdose...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, Julia, Stock, Christopher J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429207/
https://www.ncbi.nlm.nih.gov/pubmed/32848444
http://dx.doi.org/10.2147/PGPM.S261424
_version_ 1783571241778544640
author Boyle, Julia
Stock, Christopher J
author_facet Boyle, Julia
Stock, Christopher J
author_sort Boyle, Julia
collection PubMed
description PURPOSE: The purpose is to characterize the CYP2D6 genotype and predict the phenotype of decedents of opioid overdose to determine if the ultrarapid (UM) phenotype is over-represented in opioid overdose deaths. CYP2D6 is the enzyme responsible for metabolism of various opioids implicated in overdose. The UM group may be at greater risk for overdose due to the rapid metabolism of hydrocodone, oxycodone, or tramadol to more active/potent metabolites than their peers with (poor) PM, (intermediate) IM, or (extensive) EM metabolic phenotypes. PATIENTS AND METHODS: Blood samples obtained during autopsy following an opioid overdose from 75 US military veteran decedents prescribed hydrocodone, oxycodone, or tramadol from one VA medical center were analyzed. DNA extraction, CYP2D6 genotyping, and copy number variation (CNV) testing were performed using the iPLEX(®) genotyping assay and MassARRAY. Phenotype prediction was based on Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations. Toxicology results were obtained from Medical Examiner reports of the deceased. Prescription medication information was extracted from archived medical records. RESULTS: The majority of the sample had a phenotype of EM metabolizer (75%), with 7% of the total sample having a UM metabolizer phenotype. In addition to hydrocodone, oxycodone, and tramadol (found in 41% of opioid positive samples), other opioids found in toxicology tests included diacetylmorphine, fentanyl, buprenorphine, and methadone. Two or more substances, including alcohol, benzodiazepines, and other potentially sedating medications, were found in nearly half of the opioid positive toxicology samples. CONCLUSION: In this study, 7% of veteran decedents of opioid overdose had CYP2D6 UM metabolic phenotype. The small sample size precludes a conclusion that the frequency of UM phenotype is greater than expected in North American Caucasian groups. The findings in this study do not support the hypothesis that the UM phenotype is over-represented in opioid overdose.
format Online
Article
Text
id pubmed-7429207
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74292072020-08-25 CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review Boyle, Julia Stock, Christopher J Pharmgenomics Pers Med Short Report PURPOSE: The purpose is to characterize the CYP2D6 genotype and predict the phenotype of decedents of opioid overdose to determine if the ultrarapid (UM) phenotype is over-represented in opioid overdose deaths. CYP2D6 is the enzyme responsible for metabolism of various opioids implicated in overdose. The UM group may be at greater risk for overdose due to the rapid metabolism of hydrocodone, oxycodone, or tramadol to more active/potent metabolites than their peers with (poor) PM, (intermediate) IM, or (extensive) EM metabolic phenotypes. PATIENTS AND METHODS: Blood samples obtained during autopsy following an opioid overdose from 75 US military veteran decedents prescribed hydrocodone, oxycodone, or tramadol from one VA medical center were analyzed. DNA extraction, CYP2D6 genotyping, and copy number variation (CNV) testing were performed using the iPLEX(®) genotyping assay and MassARRAY. Phenotype prediction was based on Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations. Toxicology results were obtained from Medical Examiner reports of the deceased. Prescription medication information was extracted from archived medical records. RESULTS: The majority of the sample had a phenotype of EM metabolizer (75%), with 7% of the total sample having a UM metabolizer phenotype. In addition to hydrocodone, oxycodone, and tramadol (found in 41% of opioid positive samples), other opioids found in toxicology tests included diacetylmorphine, fentanyl, buprenorphine, and methadone. Two or more substances, including alcohol, benzodiazepines, and other potentially sedating medications, were found in nearly half of the opioid positive toxicology samples. CONCLUSION: In this study, 7% of veteran decedents of opioid overdose had CYP2D6 UM metabolic phenotype. The small sample size precludes a conclusion that the frequency of UM phenotype is greater than expected in North American Caucasian groups. The findings in this study do not support the hypothesis that the UM phenotype is over-represented in opioid overdose. Dove 2020-08-11 /pmc/articles/PMC7429207/ /pubmed/32848444 http://dx.doi.org/10.2147/PGPM.S261424 Text en © 2020 Boyle and Stock. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Boyle, Julia
Stock, Christopher J
CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title_full CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title_fullStr CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title_full_unstemmed CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title_short CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review
title_sort cyp2d6 expression in veterans experiencing opioid overdose: a postmortem review
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429207/
https://www.ncbi.nlm.nih.gov/pubmed/32848444
http://dx.doi.org/10.2147/PGPM.S261424
work_keys_str_mv AT boylejulia cyp2d6expressioninveteransexperiencingopioidoverdoseapostmortemreview
AT stockchristopherj cyp2d6expressioninveteransexperiencingopioidoverdoseapostmortemreview